The General Assembly finds that: (1) The State Board of Finance has a fiduciary obligation to explore cost-effective treatments for its members; (2) There are emerging technologies that could serve as cost-effective alternatives to surgical procedures; and (3) Clinical organizations are increasingly providing public guidance on quality treatment practices. Amended by Act 2021, No. 1004,§ 25, eff. 4/28/2021. Added by Act 2019, No. 391,§ 10, eff. 7/24/2019. The General Assembly finds that: (1) The State Board of Finance has a fiduciary obligation to explore cost-effective treatments for its members; (2) There are emerging technologies that could serve as cost-effective alternatives to surgical procedures; and (3) Clinical organizations are increasingly providing public guidance on quality treatment practices. Amended by Act 2021, No. 1004,§ 25, eff. 4/28/2021. Added by Act 2019, No. 391,§ 10, eff. 7/24/2019. The General Assembly finds that: (1) The State Board of Finance has a fiduciary obligation to explore cost-effective treatments for its members; (2) There are emerging technologies that could serve as cost-effective alternatives to surgical procedures; and (3) Clinical organizations are increasingly providing public guidance on quality treatment practices. Amended by Act 2021, No. 1004,§ 25, eff. 4/28/2021. Added by Act 2019, No. 391,§ 10, eff. 7/24/2019. The General Assembly finds that: (1) The State Board of Finance has a fiduciary obligation to explore cost-effective treatments for its members; (2) There are emerging technologies that could serve as cost-effective alternatives to surgical procedures; and (3) Clinical organizations are increasingly providing public guidance on quality treatment practices.
‹ Prev All Arkansas sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.